Hand-out
Press Releases
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results
Announced acceptance and Priority Review by the United States Food and Drug Administration (FDA) of the new drug application (NDA) for troriluzole in all-genotype spinocerebellar ataxia; expected Prescription Drug User
